Timberlyne Therapeutics, a San Diego, CA-based clinical-stage biopharmaceutical firm targeted on the event of recent therapies for autoimmune issues, raised $180M in Sequence A funding.
The spherical was led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Companions, with participation from Boyu Capital, Lilly Asia Ventures, Braidwell LP, and 3H Well being Funding.
The corporate intends to make use of the funds to broaden operations and its R&D sector.
Fashioned by Mountainfield Enterprise Companions, a biopharma firm creation agency, in partnership with Keymed Biosciences Inc. (HKEX: 02162), Timberlyne Therapeutics is a clinical-stage biopharmaceutical firm targeted on the event and commercialization of transformational therapies for unmet medical wants. Its lead program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38.
By focusing on CD38, which is extremely expressed on plasma cells, NK cells, and different immune cells, CM313 modulates a number of immune cell varieties resulting in each speedy and sturdy responses throughout a variety of autoimmune illnesses and cancers.
Timberlyne has obtained unique growth and commercialization rights to CM313 worldwide outdoors of larger China from Keymed Biosciences. Underneath the phrases of the licensing settlement, Keymed will obtain an undisclosed upfront cost, in addition to future money milestones, royalties on any potential future web gross sales, and fairness possession in Timberlyne. Keymed retains growth and commercialization rights in larger China.
FinSMEs
10/01/2025
